Planning

Additive solutions for the Suspension of Blood Products

  • NHS Blood and Transplant

F01: Prior information notice (prior information only)

Notice identifier: 2022/S 000-036345

Procurement identifier (OCID): ocds-h6vhtk-0393a2

Published 22 December 2022, 11:13am



Section one: Contracting authority

one.1) Name and addresses

NHS Blood and Transplant

500 North Bristol Park

Bristol

BS34 7QH

Contact

Samantha Rix

Email

samantha.rix@nhsbt.nhs.uk

Telephone

+44 7385972251

Country

United Kingdom

Region code

UKK11 - Bristol, City of

National registration number

NHS Blood and Transplant

Internet address(es)

Main address

https://www.nhsbt.nhs.uk/

Buyer's address

https://www.nhsbt.nhs.uk/

one.3) Communication

Additional information can be obtained from the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

https://health-family.force.com/s/Welcome

one.4) Type of the contracting authority

Body governed by public law

one.5) Main activity

Health


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

Additive solutions for the Suspension of Blood Products

Reference number

C120135

two.1.2) Main CPV code

  • 33194220 - Blood-transfusion supplies

two.1.3) Type of contract

Supplies

two.1.4) Short description

This Prior Information Notice (PIN) is separate to any tender opportunity, its purpose is to consult and gauge interest in the market, to improve NHSBT’s knowledge of 'Additive Solutions for the Suspension of Blood Products' available in the marketplace.

two.1.5) Estimated total value

Value excluding VAT: £5,500,000

two.1.6) Information about lots

This contract is divided into lots: No

two.2) Description

two.2.3) Place of performance

NUTS codes
  • UK - United Kingdom
Main site or place of performance

United Kingdom, Ireland, Australia and New Zealand

two.2.4) Description of the procurement

NHS Blood and Transplant (NHSBT) is a Special Health Authority in the NHS and is responsible for the provision of blood components and a range of associated laboratory and patient therapeutic services to hospitals in England.

NHSBT wishes to inform the market of prospective requirements, as far as their details are known at this time for the suspension of apheresis platelets, whole blood derived pooled platelets and specialist red cell products by the establishment of a Framework Agreement with the following Blood Establishments as beneficiaries - NHS Blood and Transplant; the Welsh Blood Service (WBS); the Northern Ireland Blood Transfusion Service (NIBTS); the Scottish National Blood Transfusion Service (SNBTS); the Australian Red Cross Lifeblood (ARCL), the New Zealand Blood Service (NZBS) and the Irish Blood Transfusion Service (IBTS).

Description of the goods to be purchased:
Additive solution for the suspension of platelets, granulocytes and other components derived from whole blood; Additive solution for the suspension of single donor apheresis derived platelets and SAGM solution for the routine washing and re-suspension of red cells during the production of specialist blood products in accordance with the Guidelines for the Blood Transfusion Services in the UK details of which can be found at the following website https://www.transfusionguidelines.org/red-book

Supplier Engagement Meeting(s) via Microsoft TEAMS will be held in late January or early February 2023.

The format of the Supplier Engagement Meeting will be communicated to those organisations that respond to this PIN.

Expressions of interest for the Supplier Engagement activity should be submitted by email to Samantha.rix@nhsbt.nhs.uk no later than 16:00 GMT on 13 January 2023.

two.3) Estimated date of publication of contract notice

1 March 2023


Section four. Procedure

four.1) Description

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes